NEW YORK, Oct. 24 (Xinhua) — Oil prices declined on Friday.
The West Texas Intermediate for December delivery dropped 28 cents, or 0.47 percent, to settle at 61.50 U.S. dollars a barrel on the New York Mercantile Exchange. Brent crude for December delivery lost 5 cents, or 0.08 percent, to settle at 65.94 dollars a barrel on the London ICE Futures Exchange. Enditem
Since its launch on September 30, OpenAI’s Sora app has dominated the iOS App Store charts, thanks to its easy breezy AI video generation and an initially loose interpretation of copyright laws. On Friday, its reign came to an end. Your new…
Spokesperson says national security and protection of Pakistani citizens are more important than any trade activity
Foreign Office Spokesperson Tahir Hussain Andrabi. PHOTO: Radio Pakistan
Hailey Bieber has shut down…
As organizations move fully to Windows 11, consistent access to and control over firmware settings is becoming a governance and security concern, not just a troubleshooting task. Enterprise IT leaders and endpoint managers need clear, repeatable…
Camila Cabello landed on the Billboard Hot 100 with “First Man,” a song dedicated to her father Alejandro, who broke down in tears when she wowed the Grammys with a live performance in 2020. Next week, she’ll turn her attention to her…
During an epidemic, some of the most critical questions for healthcare decision-makers are the hardest ones to answer: When will the epidemic peak, how many people will need treatment at once and how long will that peak level of…
The FDA has approved revumenib (Revuforj; Syndax Pharmaceuticals) for patients 1 year and older with relapsed or refractory
The
According to the updated results presented at EHA, the median time to first CR/CRh was 2.8 months with a median duration of 4.7 months. The overall response rate was 48.1%.
“The expanded FDA approval of Revuforj marks a major advancement in the management of acute leukemia patients,” Joshua F. Zeidner, MD, chief, Leukemia Research at the University of North Carolina, Lineberger Comprehensive Cancer Center, said in a
The data published in Blood also showed that responses were observed across various subgroups, regardless of previous hematopoietic stem cell transplantation (HSCT) and number of lines of therapy.2 CR/CRh rates were also similar among adults younger than 65 years or 65 years and older. Patients with previous venetoclax exposure had a CR/CRh rate of 16.7% (95% CI, 7.5%-30.2%), while patients without previous exposure had a CR/CRh rate of 43.8% (95% CI, 19.8%-70.1%).
There were 5 adult patients who achieved an overall response and underwent allogeneic HSCT while in remission, with 3 of them subsequently resuming revumenib after transplant.
In addition, 98.8% of patients experienced treatment-emergency adverse events (AEs), with 78.6% experiencing at least 1 treatment-related AE (TRAE) and 59.5% experiencing a grade 3 or higher TRAE.
Additional safety findings were:
“New treatment options are vitally needed for patients with NPM1-mutated AML whose disease has returned or not improved after previous treatment,” said Lore Gruenbaum, PhD, chief scientific officer of Blood Cancer United (formerly The Leukemia & Lymphoma Society). “The FDA approval of a precision treatment that selectively targets the pathway driving this form of AML offers new hope to patients and their loved ones.”
Revumenib was previously approved in 2024 to treat R/R acute leukemia with a KMT2A translocation for patients 1 year and older.5
References
1. FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. News release. FDA. October 24, 2025. Accessed October 24, 2025.
2. Arellano ML, Thirman MJ, DiPersio JF, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. Published online May 7, 2025. Accessed May 8, 2025. doi:10.1182/blood.2025028357
3. Joszt L. Revumenib shows efficacy in patients with AML and genetic alterations. AJMC®. June 12, 2025. Accessed October 24, 2025.
4. Syndax announces FDA approval of Revuforj (revumenib) in adult and pediatric patients with relapsed or refractory NPM1 mutated acute myeloid leukemia. News release. Syndax Pharmaceuticals. October 24, 2025. Accessed October 24, 2025.
5. Rosa K. FDA approves revumenib for R/R acute leukemia with a KMT2A translocation. OncLive®. November 15, 2204. Accessed October 24, 2025.
By William Gavin
Redwood Materials plans to meet the AI-fueled demand for energy with recycled electric-car batteries
J.B. Straubel is a former Tesla executive who left to focus on his energy startup, Redwood Materials.
A previous version of this report incorrectly listed Redwood’s valuation as of a 2023 funding round.
The battery-recycling company founded by an ex-Tesla Inc. executive can count a high-profile artificial-intelligence company among investors in its latest funding round.
Redwood Materials said Thursday it had raised $350 million in a round led by the venture-capital firm Eclipse and Nvidia Corp.’s (NVDA) venture-capital arm, NVentures. Nvidia’s contribution to the round was not disclosed, and a representative did not immediately return a request for comment.
The fundraise comes as major AI players are scrambling to meet their power needs and as the U.S. is facing difficulties building out domestic mineral-supply chains. Currently, China is – by far – the dominant force in the global supply chains for cobalt, nickel and other minerals. And rising tensions between China and the U.S. have stoked worries that some companies, including carmakers, may get cut off from lithium-ion batteries and battery materials.
Don’t miss: Quantum stocks are rising. Why they may be the Trump White House’s next investment.
“This is a pivotal time for both Redwood and the United States, as curtailment in international supplies overlaps with intense domestic demand growth for these same materials and energy products,” the company said in a statement.
Redwood said it would use the new cash to expand its growing energy-storage business, which it launched in June under the name Redwood Energy and which seeks to meet the quickly escalating demand for energy needed for AI data centers. By 2030, global power demand from data centers is set to grow 165% compared with 2023, according to Goldman Sachs.
“AI is several things. AI is energy, AI is chips, the models and the application,” Nvidia CEO Jensen Huang said in a recent interview with CNBC’s “Squawk Box.” “And we need more energy.”
Redwood believes it already has the supply chains necessary to match its ambitions. The company has said it receives batteries equivalent to 250,000 electric vehicles annually, or about 90% of all lithium-ion batteries and battery materials recycled in North America.
Redwood’s core business involves recycling scrap from consumer electronics and batteries, extracting minerals like cobalt and nickel and selling those components back to partners and battery suppliers, including Toyota Motor Corp (JP:7203).
Now it says it won’t take battery packs apart immediately, instead diverting what power remains to fuel low-cost, large-scale energy-storage systems. Once that energy is fully drained, the batteries are sent to be scrapped for parts as usual.
“Low-cost, large-scale battery energy storage has emerged as the most immediate and scalable solution to enable AI factory deployment and unlock stranded grid and generation capacity,” Redwood said in a statement.
Redwood was founded in 2017 by J.B. Straubel, a Tesla (TSLA) co-founder and executive who left the company to scale his startup. Straubel’s former employer is also seeking to meet growing energy demand.
See more: This underrated Tesla business deserves more attention – and it’s not AI
Beyond expanding its energy business, Redwood said it will also use the new capital to expand its refining and material-production capacity and build out its engineering and operations teams. The company was valued at $5 billion in late 2023, following its previous fundraising round, according to TechCrunch.
The company is currently valued at about $6 billion, according to a source familiar with the matter.
-William Gavin
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-24-25 1518ET
Copyright (c) 2025 Dow Jones & Company, Inc.
Netflix has shut down Boss Fight Entertainment, the studio behind its hit mobile game based on the “Squid Game” franchise.
The two games the developer has released for the streamer, the “Netflix Stories” (which had…